Contraceptive regimen including reduced level of estrogen
A contraceptive regimen that provides for a reduced level of estrogen. The contraceptive regimen can be used for the treatment of symptoms associated with endometriosis or fibroids.
1. A method of contraception or treating one or more symptoms of endometriosis or fibroids for a female in need thereof comprising steps:
a) administering to the female, daily, about 1 mcg to 2.5 mcg of ethinyl estradiol and about 0.075 mg to about 5 mg of a progestogen for about 20 to about 26 consecutive days of a 28-day cycle; and
b) administering to the female, daily, about 1 mcg to 2.5 mcg of ethinyl estradiol in the absence of any progestogen for about 1 to about 6 consecutive days, of the 28-day cycle following the step a); and
c) administering to the female, daily, a placebo for a remainder of the 28-day cycle.
2. The method of claim 1 , wherein ethinyl estradiol and the progestogen in the step a) are administered for 24 consecutive days.
3. The method of claim 1 , wherein ethinyl estradiol in the step b) is administered for 1 day.
4. The method of claim 1 , wherein ethinyl estradiol in the step b) is administered for 2 consecutive days.
5. The method of claim 1 , wherein ethinyl estradiol in the step b) is administered for 3 consecutive days.
6. The method of claim 1 , wherein following the completion of the 28-day cycle, a new 28-day cycle begins.
7. The method of claim 1 , wherein a daily amount of the progestogen administered in the step a) is about 1.0 mg.
8. The method of claim 1 , wherein the progestogen is norethindrone acetate or desogestrel.
9. The method of claim 7 , wherein the progestogen is norethindrone acetate.
10. The method of claim 1 , wherein the female is not administered a gonadotropin-releasing hormone antagonist or a gonadotropin-releasing hormone agonist.
11. A method of contraception for a female in need thereof comprising steps:
a) administering to the female, daily, 2.5 mcg of ethinyl estradiol and 1.0 mg of norethindrone acetate for 24 consecutive days of a 28-day cycle;
b) administering to the female, daily, 2.5 mcg of ethinyl estradiol in the absence of any progestogen for 2 days of the 28-day cycle following the step a); and
c) administering to the female, daily, a placebo for 2 days of the 28-day cycle following the step b).